Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Unmet needs in immunotherapy for prostate cancer

Russell Kent Pachynski • 17 Feb 2023
GU Cancers 2023
Genitourinary Cancer Prostate Cancer

Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, talks on unmet needs in regards to immunotherapy for prostate cancer, focusing on the treatment of patients with bone metastasis. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Russell Kent Pachynski

1:37
Novel immunotherapeutic approaches under evaluation in patients with mCRPC
Russell Kent Pachynski • 16 Feb 2023
1:14
The implications of CheckMate 650 for the clinical management of post-chemotherapy mCRPC
Russell Kent Pachynski • 16 Feb 2023
0:50
CheckMate 650: nivolumab + ipilimumab, ipilimumab alone, or cabazitaxel in mCRPC
Russell Kent Pachynski • 18 Feb 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals